Cargando…
Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French Society of Pediatric Oncology
To assess the relevance of MYCN amplification and bone lesions in stage 4 neuroblastoma (NB) in infants aged <1 year, 51 infants with stage 4 NB were enrolled. Three groups of patients were defined according to the type of metastases and the resectability of the primary tumour. Group I comprised...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2000
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363565/ https://www.ncbi.nlm.nih.gov/pubmed/10993641 http://dx.doi.org/10.1054/bjoc.2000.1412 |
_version_ | 1782153736456503296 |
---|---|
author | Minard, V Hartmann, O Peyroulet, M C Michon, J Coze, C Defachelle, A S Lejars, O Perel, Y Bergeron, C Boutard, P Leverger, G Stephan, J L Thyss, A Chastagner, P Couillault, G Devalck, C Lutz, P Mechinaud, F Millot, F Plantaz, D Rialland, X Rubie, H |
author_facet | Minard, V Hartmann, O Peyroulet, M C Michon, J Coze, C Defachelle, A S Lejars, O Perel, Y Bergeron, C Boutard, P Leverger, G Stephan, J L Thyss, A Chastagner, P Couillault, G Devalck, C Lutz, P Mechinaud, F Millot, F Plantaz, D Rialland, X Rubie, H |
author_sort | Minard, V |
collection | PubMed |
description | To assess the relevance of MYCN amplification and bone lesions in stage 4 neuroblastoma (NB) in infants aged <1 year, 51 infants with stage 4 NB were enrolled. Three groups of patients were defined according to the type of metastases and the resectability of the primary tumour. Group I comprised 21 infants with radiologically detectable bone lesions, Group II 22 patients with an unresectable primary tumour and Group III eight patients with only metaiodobenzylguanidine (MIBG) skeletal uptake. MYCN oncogene content was assayed in 47/51 tumours and found to be amplified in 17 (37%). The 5-year event-free survival (EFS) rate of these 51 infants was 64.1% (± 7.1%). In a univariate analysis, bone lesions, MYCN amplification, urinary vanillylmandelic/homovanillic acid ratio and serum ferritin levels adversely influenced outcome. In the multivariate analysis, radiologically detectable bone lesions were the most powerful unfavourable prognostic indicator: the EFS rate was 27.2% for these infants compared to 90% for infants without bone lesions (P < 0.0001). Our data emphasize the poor prognosis of infants affected by stage 4 NB with bone lesions, especially when associated with MYCN amplification. Given the poor results in this group whatever the treatment, new therapeutic approaches need to be investigated in the future. © 2000 Cancer Research Campaign |
format | Text |
id | pubmed-2363565 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2000 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23635652009-09-10 Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French Society of Pediatric Oncology Minard, V Hartmann, O Peyroulet, M C Michon, J Coze, C Defachelle, A S Lejars, O Perel, Y Bergeron, C Boutard, P Leverger, G Stephan, J L Thyss, A Chastagner, P Couillault, G Devalck, C Lutz, P Mechinaud, F Millot, F Plantaz, D Rialland, X Rubie, H Br J Cancer Regular Article To assess the relevance of MYCN amplification and bone lesions in stage 4 neuroblastoma (NB) in infants aged <1 year, 51 infants with stage 4 NB were enrolled. Three groups of patients were defined according to the type of metastases and the resectability of the primary tumour. Group I comprised 21 infants with radiologically detectable bone lesions, Group II 22 patients with an unresectable primary tumour and Group III eight patients with only metaiodobenzylguanidine (MIBG) skeletal uptake. MYCN oncogene content was assayed in 47/51 tumours and found to be amplified in 17 (37%). The 5-year event-free survival (EFS) rate of these 51 infants was 64.1% (± 7.1%). In a univariate analysis, bone lesions, MYCN amplification, urinary vanillylmandelic/homovanillic acid ratio and serum ferritin levels adversely influenced outcome. In the multivariate analysis, radiologically detectable bone lesions were the most powerful unfavourable prognostic indicator: the EFS rate was 27.2% for these infants compared to 90% for infants without bone lesions (P < 0.0001). Our data emphasize the poor prognosis of infants affected by stage 4 NB with bone lesions, especially when associated with MYCN amplification. Given the poor results in this group whatever the treatment, new therapeutic approaches need to be investigated in the future. © 2000 Cancer Research Campaign Nature Publishing Group 2000-10 /pmc/articles/PMC2363565/ /pubmed/10993641 http://dx.doi.org/10.1054/bjoc.2000.1412 Text en Copyright © 2000 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Regular Article Minard, V Hartmann, O Peyroulet, M C Michon, J Coze, C Defachelle, A S Lejars, O Perel, Y Bergeron, C Boutard, P Leverger, G Stephan, J L Thyss, A Chastagner, P Couillault, G Devalck, C Lutz, P Mechinaud, F Millot, F Plantaz, D Rialland, X Rubie, H Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French Society of Pediatric Oncology |
title | Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French Society of Pediatric Oncology |
title_full | Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French Society of Pediatric Oncology |
title_fullStr | Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French Society of Pediatric Oncology |
title_full_unstemmed | Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French Society of Pediatric Oncology |
title_short | Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French Society of Pediatric Oncology |
title_sort | adverse outcome of infants with metastatic neuroblastoma, mycn amplification and/or bone lesions: results of the french society of pediatric oncology |
topic | Regular Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363565/ https://www.ncbi.nlm.nih.gov/pubmed/10993641 http://dx.doi.org/10.1054/bjoc.2000.1412 |
work_keys_str_mv | AT minardv adverseoutcomeofinfantswithmetastaticneuroblastomamycnamplificationandorbonelesionsresultsofthefrenchsocietyofpediatriconcology AT hartmanno adverseoutcomeofinfantswithmetastaticneuroblastomamycnamplificationandorbonelesionsresultsofthefrenchsocietyofpediatriconcology AT peyrouletmc adverseoutcomeofinfantswithmetastaticneuroblastomamycnamplificationandorbonelesionsresultsofthefrenchsocietyofpediatriconcology AT michonj adverseoutcomeofinfantswithmetastaticneuroblastomamycnamplificationandorbonelesionsresultsofthefrenchsocietyofpediatriconcology AT cozec adverseoutcomeofinfantswithmetastaticneuroblastomamycnamplificationandorbonelesionsresultsofthefrenchsocietyofpediatriconcology AT defachelleas adverseoutcomeofinfantswithmetastaticneuroblastomamycnamplificationandorbonelesionsresultsofthefrenchsocietyofpediatriconcology AT lejarso adverseoutcomeofinfantswithmetastaticneuroblastomamycnamplificationandorbonelesionsresultsofthefrenchsocietyofpediatriconcology AT perely adverseoutcomeofinfantswithmetastaticneuroblastomamycnamplificationandorbonelesionsresultsofthefrenchsocietyofpediatriconcology AT bergeronc adverseoutcomeofinfantswithmetastaticneuroblastomamycnamplificationandorbonelesionsresultsofthefrenchsocietyofpediatriconcology AT boutardp adverseoutcomeofinfantswithmetastaticneuroblastomamycnamplificationandorbonelesionsresultsofthefrenchsocietyofpediatriconcology AT levergerg adverseoutcomeofinfantswithmetastaticneuroblastomamycnamplificationandorbonelesionsresultsofthefrenchsocietyofpediatriconcology AT stephanjl adverseoutcomeofinfantswithmetastaticneuroblastomamycnamplificationandorbonelesionsresultsofthefrenchsocietyofpediatriconcology AT thyssa adverseoutcomeofinfantswithmetastaticneuroblastomamycnamplificationandorbonelesionsresultsofthefrenchsocietyofpediatriconcology AT chastagnerp adverseoutcomeofinfantswithmetastaticneuroblastomamycnamplificationandorbonelesionsresultsofthefrenchsocietyofpediatriconcology AT couillaultg adverseoutcomeofinfantswithmetastaticneuroblastomamycnamplificationandorbonelesionsresultsofthefrenchsocietyofpediatriconcology AT devalckc adverseoutcomeofinfantswithmetastaticneuroblastomamycnamplificationandorbonelesionsresultsofthefrenchsocietyofpediatriconcology AT lutzp adverseoutcomeofinfantswithmetastaticneuroblastomamycnamplificationandorbonelesionsresultsofthefrenchsocietyofpediatriconcology AT mechinaudf adverseoutcomeofinfantswithmetastaticneuroblastomamycnamplificationandorbonelesionsresultsofthefrenchsocietyofpediatriconcology AT millotf adverseoutcomeofinfantswithmetastaticneuroblastomamycnamplificationandorbonelesionsresultsofthefrenchsocietyofpediatriconcology AT plantazd adverseoutcomeofinfantswithmetastaticneuroblastomamycnamplificationandorbonelesionsresultsofthefrenchsocietyofpediatriconcology AT riallandx adverseoutcomeofinfantswithmetastaticneuroblastomamycnamplificationandorbonelesionsresultsofthefrenchsocietyofpediatriconcology AT rubieh adverseoutcomeofinfantswithmetastaticneuroblastomamycnamplificationandorbonelesionsresultsofthefrenchsocietyofpediatriconcology |